MCID: FML037
MIFTS: 52

Female Breast Cancer

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Female Breast Cancer

MalaCards integrated aliases for Female Breast Cancer:

Name: Female Breast Cancer 11 14
Female Breast Carcinoma 11 14 71
Malignant Neoplasm of Female Breast 71
Mammary Carcinoma of Female Breast 11
Carcinoma of Female Breast 11

Classifications:



External Ids:

Disease Ontology 11 DOID:0050671 DOID:7843
NCIt 49 C2918
UMLS 71 C0007104 C0235653

Summaries for Female Breast Cancer

Disease Ontology 11 Female breast cancer: A breast cancer that develops from breast tissue in females.

Female breast carcinoma: A breast carcinoma that is manifested in the female breast.

MalaCards based summary: Female Breast Cancer, also known as female breast carcinoma, is related to tubular adenocarcinoma and breast-ovarian cancer, familial 2. An important gene associated with Female Breast Cancer is PGR (Progesterone Receptor), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Toremifene and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and prostate, and related phenotypes are Increased cell death in HCT116 cells and homeostasis/metabolism

Related Diseases for Female Breast Cancer

Diseases related to Female Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 519)
# Related Disease Score Top Affiliating Genes
1 tubular adenocarcinoma 30.4 PGR ESR1 ERBB2 CTSD
2 breast-ovarian cancer, familial 2 30.4 BRCA2 BRCA1
3 hereditary breast cancer 30.4 BRCA2 BRCA1
4 progesterone-receptor positive breast cancer 30.3 PGR ESR1 ERBB2 CYP19A1
5 mammary paget's disease 30.1 PIP PGR ESR1 ERBB2 AR
6 ovarian cyst 30.0 PGR ESR2 ESR1 CYP19A1 BRCA1
7 skin carcinoma 30.0 TP53 KRT5 ERBB2 EGFR CDK4 BCL2
8 cervix carcinoma 30.0 TP53 PGR ESR1 ERBB2 EGFR BCL2
9 breast disease 29.9 TP53 PGR KLK3 ESR2 ESR1 ERBB2
10 sporadic breast cancer 29.9 TP53 PGR KRT5 ESR1 ERBB2 BRCA2
11 adenoid cystic carcinoma 29.9 TP53 PGR ERBB2 EGFR CDK4 BRCA1
12 melanoma, uveal 29.9 TP53 ERBB2 EGFR CDK4 BRCA1 BCL2
13 diabetes mellitus 29.9 TP53 KLK3 ESR2 ESR1 EGFR CYP19A1
14 inherited cancer-predisposing syndrome 29.8 TP53 MLH1 EGFR CDK4 BRCA2 BRCA1
15 bap1 tumor predisposition syndrome 29.8 TP53 MLH1 EGFR CDK4 BRCA2 BRCA1
16 infertility 29.8 PGR MLH1 ESR2 ESR1 CYP19A1 AR
17 gynecomastia 29.8 PGR KLK3 ESR2 ESR1 ERBB2 CYP19A1
18 hereditary breast ovarian cancer syndrome 29.8 TP53 PGR MLH1 ESR1 ERBB2 EGFR
19 breast fibroadenoma 29.7 TP53 PGR KRT5 ESR1 ERBB2 EGFR
20 peripheral nervous system disease 29.6 TP53 ESR1 ERBB2 EGFR CDK4 BRCA1
21 adenocarcinoma 29.6 TP53 MLH1 KLK3 ERBB2 EGFR CDK4
22 lynch syndrome 29.5 TP53 PGR MLH1 ESR1 ERBB2 EGFR
23 endometrial cancer 29.4 TP53 PGR MLH1 ESR2 ESR1 ERBB2
24 estrogen-receptor positive breast cancer 29.3 TP53 PGR ESR2 ESR1 ERBB2 EGFR
25 breast cancer 29.2 TP53 TOP2A PIP PGR MLH1 KRT5
26 ductal carcinoma in situ 29.2 TP53 PIP PGR KRT5 GATA3 ESR2
27 breast ductal carcinoma 29.0 TP53 PIP PGR KRT5 ESR2 ESR1
28 breast carcinoma in situ 29.0 TP53 PIP PGR KRT5 GATA3 ESR2
29 hepatocellular carcinoma 28.9 TP53 TOP2A PGR MLH1 ESR1 ERBB2
30 ovarian cancer 28.4 TP53 TOP2A PGR MLH1 KLK3 ESR2
31 prostate cancer 28.2 TP53 TOP2A PGR MLH1 KRT5 KLK3
32 female breast nipple and areola cancer 11.1
33 female breast central part cancer 11.1
34 female breast lower-outer quadrant cancer 11.1
35 female breast upper-inner quadrant cancer 11.1
36 female breast lower-inner quadrant cancer 11.1
37 female breast axillary tail cancer 11.1
38 female breast upper-outer quadrant cancer 11.1
39 uterine corpus adenosarcoma 10.5 PGR ESR1
40 scirrhous adenocarcinoma 10.4 PGR ERBB2
41 adult cystic nephroma 10.4 PGR ESR1
42 her2-receptor negative breast cancer 10.4 PGR ERBB2
43 vagina leiomyosarcoma 10.4 PGR ESR1
44 vulvar benign neoplasm 10.4 PGR ESR1
45 hereditary site-specific ovarian cancer syndrome 10.4 BRCA2 BRCA1
46 ovary transitional cell carcinoma 10.4 BRCA2 BRCA1
47 apocrine adenosis of breast 10.4 TP53 ERBB2
48 cancerophobia 10.4 BRCA2 BRCA1
49 subserous uterine fibroid 10.4 PGR CYP19A1
50 tetraploidy 10.4 TP53 BRCA2

Comorbidity relations with Female Breast Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Breast Fibroadenosis
Deficiency Anemia Fat Necrosis of Breast
Hypertension, Essential Hypothyroidism
Mastitis Microglandular Adenosis
Neutropenia

Graphical network of the top 20 diseases related to Female Breast Cancer:



Diseases related to Female Breast Cancer

Symptoms & Phenotypes for Female Breast Cancer

GenomeRNAi Phenotypes related to Female Breast Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 ANKRD30A AR BCL2 BRCA1 BRCA2 CDK4
2 no effect GR00402-S-2 10.19 AR BCL2 BRCA1 BRCA2 CDK4 CTSD
3 Increased cell death in HCT116 cells GR00103-A-0 8.65 TOP2A

MGI Mouse Phenotypes related to Female Breast Cancer:

45 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.46 AR BCL2 BRCA1 BRCA2 CDK4 CTSD
2 endocrine/exocrine gland MP:0005379 10.45 AR BCL2 BRCA1 BRCA2 CDK4 CTSD
3 growth/size/body region MP:0005378 10.44 AR BCL2 BRCA1 BRCA2 CDK4 CTSD
4 normal MP:0002873 10.42 AR BRCA1 BRCA2 CDK4 CYP19A1 EGFR
5 nervous system MP:0003631 10.42 AR BCL2 BRCA1 BRCA2 CDK4 CTSD
6 neoplasm MP:0002006 10.4 AR BCL2 BRCA1 BRCA2 CDK4 EGFR
7 muscle MP:0005369 10.4 AR BCL2 BRCA1 CDK4 CYP19A1 EGFR
8 digestive/alimentary MP:0005381 10.4 AR BCL2 BRCA1 BRCA2 CDK4 CTSD
9 cellular MP:0005384 10.36 AR BCL2 BRCA1 BRCA2 CDK4 CTSD
10 renal/urinary system MP:0005367 10.34 AR BCL2 BRCA1 CDK4 CYP19A1 EGFR
11 immune system MP:0005387 10.3 AR BCL2 BRCA1 BRCA2 CDK4 CTSD
12 cardiovascular system MP:0005385 10.28 AR BCL2 BRCA1 CDK4 CYP19A1 EGFR
13 limbs/digits/tail MP:0005371 10.27 AR BRCA1 BRCA2 EGFR ERBB2 ESR1
14 embryo MP:0005380 10.25 AR BCL2 BRCA1 BRCA2 CDK4 EGFR
15 pigmentation MP:0001186 10.22 AR BCL2 BRCA1 CDK4 CYP19A1 EGFR
16 adipose tissue MP:0005375 10.22 AR BCL2 BRCA1 CYP19A1 EGFR ESR1
17 behavior/neurological MP:0005386 10.22 AR BCL2 BRCA1 BRCA2 CDK4 CTSD
18 reproductive system MP:0005389 10.22 AR BCL2 BRCA1 BRCA2 CDK4 CYP19A1
19 liver/biliary system MP:0005370 10.19 AR CDK4 CYP19A1 EGFR ESR1 ESR2
20 hearing/vestibular/ear MP:0005377 10.09 BCL2 CTSD CYP19A1 EGFR ESR2 GATA3
21 hematopoietic system MP:0005397 10.09 AR BCL2 BRCA1 BRCA2 CDK4 CTSD
22 craniofacial MP:0005382 10.08 AR BCL2 CDK4 EGFR ERBB2 GATA3
23 skeleton MP:0005390 10.03 AR BRCA1 BRCA2 CDK4 CYP19A1 EGFR
24 mortality/aging MP:0010768 9.86 AR BCL2 BRCA1 BRCA2 CDK4 CTSD
25 integument MP:0010771 9.55 AR BCL2 BRCA1 BRCA2 CDK4 CTSD

Drugs & Therapeutics for Female Breast Cancer

Drugs for Female Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
2
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
3
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
4 Estrogen Receptor Modulators Phase 4
5 Selective Estrogen Receptor Modulators Phase 4
6 Platelet Aggregation Inhibitors Phase 4
7 Anesthetics, Intravenous Phase 4
8 Anesthetics, Inhalation Phase 4
9 Anesthetics, General Phase 4
10 Anesthetics Phase 4
11 Hypnotics and Sedatives Phase 4
12
Fulvestrant Approved, Investigational Phase 3 129453-61-8 17756771 104741
13
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
14
Goserelin Approved Phase 3 65807-02-5 5311128 47725
15
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
16 Antineoplastic Agents, Hormonal Phase 3
17 Estrogens Phase 3
18 Estrogen Receptor Antagonists Phase 3
19 Estrogen Antagonists Phase 3
20 Hormones Phase 3
21 Hormone Antagonists Phase 3
22 Aromatase Inhibitors Phase 3
23
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
24
Darbepoetin alfa Approved, Investigational Phase 2 209810-58-2
25
Tamoxifen Approved Phase 2 10540-29-1, 54965-24-1 2733526
26
Donepezil Approved Phase 2 120014-06-4 3152
27
Epirubicin Approved Phase 2 56420-45-2 41867
28
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
29
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286
30
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
31
Polyestradiol phosphate Approved Phase 2 28014-46-2
32 Neurotransmitter Agents Phase 2
33 Cholinergic Agents Phase 2
34 Antimitotic Agents Phase 2
35 Tubulin Modulators Phase 2
36
Epoetin Alfa Phase 2
37 Hematinics Phase 2
38 Nootropic Agents Phase 2
39 Cholinesterase Inhibitors Phase 2
40 Antimetabolites Phase 2
41 Protein Kinase Inhibitors Phase 2
42 Estradiol 3-benzoate Phase 2
43 Estradiol 17 beta-cypionate Phase 2
44
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
45
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
46 Alkylating Agents Phase 1
47 Antirheumatic Agents Phase 1
48 Antineoplastic Agents, Alkylating Phase 1
49 Immunosuppressive Agents Phase 1
50 Immunologic Factors Phase 1

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Evaluation of Adjuvant Endocrine Therapy for Operable ER-beta Positive, ER-alpha/PR Negative, Her-2 Negative Breast Cancer Patients Unknown status NCT02089854 Phase 4 Toremifene; Anastrozole
2 Does Anesthesia Technique Affect the Presence of Circulating Tumor Cells in Primary Breast Carcinoma? A Randomised Controlled Trial. Completed NCT02005770 Phase 4 Sevoflurane;Propofol
3 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of FCN-437c Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer Recruiting NCT05438810 Phase 3 FCN-437c,Fulvestrant,Goserelin acetate;Placebo,Fulvestrant,Goserelin acetate
4 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR-positive and HER2-negative Advanced Breast Cancer Recruiting NCT05439499 Phase 3 FCN-437c, Letrozole or anastrozole, Goserelin acetate;Placebo, Letrozole or anastrozole, Goserelin acetate
5 A Multicenter, Randomized, Double-blind Phase III Study:SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast Cancer Enrolling by invitation NCT04842617 Phase 3 SHR6390;placebo
6 Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer Completed NCT01671319 Phase 2 docetaxel + cyclophosphamide + pegfilgrastim
7 An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Female Breast Cancer Patients Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy Completed NCT00120692 Phase 2 Darbepoetin Alfa;Recombinant Human Erythropoietin
8 A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor Completed NCT03518138 Phase 2 Q-122;Placebo
9 A Feasibility Study of Donepezil in Female Breast Cancer Survivors With Self-Reported Cognitive Dysfunction Following Chemotherapy Completed NCT01466270 Phase 2 donepezil hydrochloride;Placebo
10 Differential Gene Regulation During Neoadjuvant Therapy Trial of Epirubicin/Cyclophosphamide (EC) vs Docetaxel/Capecitabine (DX) Regimens in Patients With Large ER-positive and ER-negative Breast Cancers: A Randomized Phase II Trial. Completed NCT01869192 Phase 2 Epirubicin;Cyclophosphamide;Docetaxel;Capecitabine
11 An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery Completed NCT03113825 Phase 2 AVB-620
12 Pilot Trial of Anastrozole and Palbociclib as First-Line Therapy and as Maintenance Therapy After First Line Chemotherapy in Hormone Receptor Positive, HER2-Negative Postmenopausal Metastatic Breast Cancer Active, not recruiting NCT02942355 Phase 2 anastrozole;Palbociclib
13 An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy Terminated NCT02540330 Phase 2 Fulvestrant
14 A Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer Terminated NCT01083641 Phase 2 Estradiol
15 Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer. Phase I Feasibility Study of Hifu-Induced Hyperthermia, LTLD and Cyclophosphamide for Metastatic Breast Cancer Recruiting NCT03749850 Phase 1 LTLD;Cyclophosphamide
16 Effect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy Unknown status NCT02243163
17 Clinical Cohort of Individual Expectations, Side Effects, Quality of Life and Adherence in Postoperative Women With Estrogen Receptor Positive Breast Cancer During Endocrine Therapy Unknown status NCT02088710
18 A Prospective, Randomized, Controlled Trial to Compare the Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serumserum Biomarkers and on PBMCs in Patients Undergoing Breast Cancer Resection Surgery Unknown status NCT03005860 2,6-Diisopropylphenol;Fluoromethyl hexafluoroisopropyl ether;Fentanyl Citrate;Atracurium Besylate
19 Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens Unknown status NCT02480933
20 Evaluating Female Sexual Dysfunction in Breast Cancer Patients After Mastectomy Unknown status NCT03153631
21 Clinical Application of Nocebo Research: Optimizing Expectations of Breast Cancer Patients to Prevent Nocebo Side Effects and Decrease of Quality of Life During Adjuvant Endocrine Therapy (DFG, NE 1635/2-1) Unknown status NCT01741883
22 Text for Health: Integrating Technology and Health Communication to Improve Health Outcomes (Part 2 of 2) Completed NCT04290585
23 Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini Completed NCT01643148
24 Metabolic Syndrome and Female Breast Cancer: a Case-control Study in Southern Brazil Completed NCT02282592
25 Synbiotic Supplementation to Reduce Anxiety Symptoms in Female Breast Cancer Survivors and/or Their Female Relatives Completed NCT04784182
26 Effects of a Traditional Chinese Exercise Program- Tai Chi on Symptom Cluster of Fatigue-sleep Disturbance-depression in Female Breast Cancer Patients: a Preliminary Randomized Controlled Trial Completed NCT04190342
27 Trends of Mastectomy and Breast-Conserving Surgery and Related Factors in Female Breast Cancer Patients Treated at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, 2009-2017 Completed NCT03762642
28 The Effects of Auricular Acupressure on Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients: A Pilot Randomized Controlled Trial Completed NCT02403037 Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)
29 Effect of Cryotherapy on Paclitaxel-Induced Peripheral Neuropathy of the Hand in Female Breast Cancer Patients: A Prospective Self-Controlled Study Completed NCT05138042
30 The Treatment For Recurrent Female Breast Cancer After Initial Endocrine Therapy Among Taiwanese Population Completed NCT02924584
31 Ultra-hypofractionated Adjuvant Radiotherapy After Breast Conserving Surgery in Breast Cancer Patients Recruiting NCT05586256
32 Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations Recruiting NCT05000502
33 Efficacy of a Brief Intervention for Female Breast CANcer Based on Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain: A 2-Arm Randomized Clinical Trial Recruiting NCT05374161
34 A Pilot Feasibility Study of a Gratitude Journaling Intervention to Enhance Well-being and Exercise Readiness in Older African American Female Breast Cancer Survivors Recruiting NCT05473026
35 Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT): a Multicenter, Observational Clinical Trial Recruiting NCT04985032
36 Intervention to Promote Uptake of Cancer Risk Counseling for Underserved Latinas Active, not recruiting NCT01230346
37 Place of Comprehensive Geriatric Assessment (CGA) in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter): Comparison Between CGA Before Surgery (Strategy A) vs. After Surgery (Strategy B) Active, not recruiting NCT03059875
38 Monocentric, Randomized Clinical Trial About the Effect of Yoga Practice on QOL, Physiological Distress and Fatigue, on Patients Affected by Breast Cancer Undergoing Adjuvant Radiotherapy Active, not recruiting NCT04775290
39 A Phase III, Randomized, Single Blind, Attention Controlled, Multi-center Study of the Effects of a Rehabilitation Intervention on Participation Restrictions of Female Breast Cancer Survivors Active, not recruiting NCT03915548
40 Diagnostic Value of Digital Breast Tomosymthesis for Breast Mass Lesions Characterization Not yet recruiting NCT04863833
41 Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors Not yet recruiting NCT05612100
42 Breast Cancer in Young Women: Is it Different? Suspended NCT01320488
43 Acupuncture for Joint Symptoms in Patients With Breast Cancer: A Randomised Controlled Trial Terminated NCT03836872
44 The Process and Outcomes of Treatment Decision-Making Communication Between Oncologists and Newly Diagnosed Female Breast-Cancer Patients Terminated NCT00891969
45 The Efficacy of Reduced-exertion High-intensity Interval Training for Improving Health and Well-being in Newly Diagnosed Female Breast Cancer Patients Withdrawn NCT03176888

Search NIH Clinical Center for Female Breast Cancer

Genetic Tests for Female Breast Cancer

Anatomical Context for Female Breast Cancer

Organs/tissues related to Female Breast Cancer:

MalaCards : Breast, Lymph Node, Prostate, Lung, Bone, Bone Marrow, Brain

Publications for Female Breast Cancer

Articles related to Female Breast Cancer:

(show top 50) (show all 2904)
# Title Authors PMID Year
1
Typhoid vaccine does not impact feelings of social connection or social behavior in a randomized crossover trial among middle-aged female breast cancer survivors. 62
36208853 2023
2
Prognostic Predictors of Mortality in Male Breast Cancer: Outcomes in an Urban Population. 62
36182676 2023
3
The preventability of cancer in Europe: A quantitative assessment of avoidable cancer cases across 17 cancer sites and 38 countries in 2020. 62
36323048 2022
4
Cancers Among Adolescents and Young Adults in Maine 2001-2017: A Descriptive Analysis and Model for Future Studies. 62
35856871 2022
5
Retrospective analysis: 5509 cases of "totally implantable venous access port systems implantation (TIVAPS) depth" assisted by digital radiography. 62
35660962 2022
6
Cohort profile: Risk and risk factors for female breast cancer after treatment for childhood and adolescent cancer: an internationally pooled cohort. 62
36344003 2022
7
Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis. 62
36094610 2022
8
Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study. 62
36240805 2022
9
Clinicopathological Features of Breast Cancer in Relation to Exposure of Cycling Reproductive Hormones: A Multicenter Retrospective Study of 14,731 Patients Diagnosed with Invasive Breast Cancer. 62
36447408 2022
10
Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer. 62
36069365 2022
11
Gynecomastia and Malignancy: A Case of Male Invasive Ductal Breast Carcinoma Treated with Neoadjuvant Chemotherapy. 62
36335424 2022
12
Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? 62
36397729 2022
13
Associations between circulating obesity-related biomarkers and prognosis in female breast cancer survivors: a systematic review of observational data in women enrolled in lifestyle intervention trials. 62
36401194 2022
14
Molecular characterization of early breast cancer onset to understand disease phenotypes in African patients. 62
36352274 2022
15
The experiences and perceptions of female breast cancer patients regarding weight management during and after treatment for oestrogen-receptor positive disease: a qualitative study. 62
36401195 2022
16
Psychometric assessment of the Concerns about Late Effects in Oncology Questionnaire (CLEO) among female breast cancer survivors. 62
35989203 2022
17
Improving resistance training prescription through the load-velocity relationship in breast cancer survivors: The case of the leg-press exercise. 62
34353234 2022
18
Breast Cancer Statistics, 2022. 62
36190501 2022
19
Milk consumption and risk of twelve cancers: A large-scale observational and Mendelian randomisation study. 62
36473423 2022
20
Cardiotoxicity in cancer patients treated with chemotherapy: A systematic review. 62
36475028 2022
21
Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan. 62
35733033 2022
22
Regional inequalities of tumour size at diagnosis in Germany: An ecological study in eight federal states. 62
35723083 2022
23
Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy. 62
36384573 2022
24
Sexual Health after a Breast Cancer Diagnosis: Addressing a Forgotten Aspect of Survivorship. 62
36431200 2022
25
Psychosocial characteristics of chronic pain in cancer survivors referred to an Australian multidisciplinary pain clinic. 62
35661330 2022
26
Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study. 62
36170687 2022
27
Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination-A Retrospective Observation. 62
36366390 2022
28
Co-designed weight management intervention for women recovering from oestrogen-receptor positive breast cancer. 62
36418985 2022
29
2D Hetero-Nanoconstructs of Black Phosphorus for Breast Cancer Theragnosis: Technological Advancements. 62
36421127 2022
30
Endoscopy-assisted latissimus dorsi muscle flap harvesting technique for immediate breast reconstruction. 62
36328867 2022
31
Breast cancer: age incidence, hormone receptor status and family history in Najaf, Iraq. 62
36420288 2022
32
The impact of APOE and smoking history on cognitive function in older, long-term breast cancer survivors. 62
36279076 2022
33
Circulating LncRNAs landscape as potential biomarkers in breast cancer. 62
36274054 2022
34
Marked Reduction in the Risk of Dementia in Patients with Breast Cancer: A Nationwide Population-Based Cohort Study. 62
36265508 2022
35
Exercise Leg Blood Flow Is Preserved in Long-term Breast Cancer Survivors Previously Treated With Anthracycline Chemotherapy. 62
36223443 2022
36
Access to Surgical Treatment for Breast Cancer in the Philippines. 62
35913672 2022
37
Early alterations in cortical morphology after neoadjuvant chemotherapy in breast cancer patients: A longitudinal magnetic resonance imaging study. 62
35665982 2022
38
Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes. 62
34687287 2022
39
Dilemma: Disclosure Experience Among Young Female Breast Cancer Survivors in China. 62
34962155 2022
40
Sexual Perception in Spanish Female Breast Cancer Survivors. Cross-Sectional Survey. 62
36357269 2022
41
A stabilized spatiotemporal kriging method for disease mapping and application to male oral cancer and female breast cancer in Taiwan. 62
36229788 2022
42
Temporal trends in social security benefits for female breast cancer in Brazil. 62
36134809 2022
43
Presentation and management of female breast cancer in Egypt. 62
36382727 2022
44
Comparison of female breast cancer between Russia and Germany: A population-based study on time trends and stage at diagnosis. 62
35841762 2022
45
Six case reports of NTHL1-associated tumor syndrome further support it as a multi-tumor predisposition syndrome. 62
36196035 2022
46
Low-Dose Extrapolation Factors Implied by Mortality and Incidence Data from the Japanese Atomic Bomb Survivor Life Span Study Data. 62
36161867 2022
47
Eating Earlier and More Frequently Is Associated With Better Diet Quality in Female Brazilian Breast Cancer Survivors Using Tamoxifen. 62
35533872 2022
48
Presentation, Diagnosis and Treatment Delays in Breast Cancer Care and Their Associations in Sri Lanka, a Low-resourced Country. 62
35672184 2022
49
Synthesis and comparative evaluation of 177Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes. 62
36127494 2022
50
The mortalities of female-specific cancers in China and other countries with distinct socioeconomic statuses: A longitudinal study. 62
36130684 2022

Variations for Female Breast Cancer

Expression for Female Breast Cancer

Search GEO for disease gene expression data for Female Breast Cancer.

Pathways for Female Breast Cancer

Pathways related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 AR BRCA1 CDK4 EGFR ERBB2 ESR1
2
Show member pathways
13.81 BCL2 BRCA1 CDK4 EGFR ERBB2 ESR1
3
Show member pathways
13.78 TP53 MLH1 ESR2 ESR1 ERBB2 EGFR
4 13.69 AR BCL2 CDK4 CTSD EGFR ERBB2
5
Show member pathways
13.68 TP53 ESR2 ESR1 ERBB2 EGFR CDK4
6
Show member pathways
12.95 BCL2 CTSD EGFR ESR1 ESR2 GATA3
7 12.82 PGR ESR1 ERBB2 EGFR CTSD
8
Show member pathways
12.81 TP53 GATA3 ESR1 BRCA1 AR
9 12.68 TP53 EGFR CDK4 BRCA1 BCL2
10
Show member pathways
12.6 TP53 MLH1 ERBB2 EGFR CDK4 BRCA2
11 12.48 TP53 TOP2A MLH1 CDK4 BRCA2 BRCA1
12
Show member pathways
12.48 TP53 ESR2 ESR1 CDK4 BRCA2 BRCA1
13
Show member pathways
12.45 TP53 ESR1 ERBB2 BCL2
14
Show member pathways
12.42 TP53 ERBB2 EGFR BCL2
15
Show member pathways
12.4 ESR2 ESR1 EGFR BCL2
16
Show member pathways
12.35 PGR ESR1 CDK4 BRCA1
17
Show member pathways
12.31 ESR2 ESR1 ERBB2 EGFR
18
Show member pathways
12.19 TP53 CDK4 BRCA1 BCL2
19
Show member pathways
12.18 TP53 ERBB2 EGFR CDK4 BCL2
20
Show member pathways
12.1 KLK3 ERBB2 EGFR AR
21
Show member pathways
12.05 PGR ESR1 ERBB2 EGFR
22
Show member pathways
12.04 TP53 PGR ESR2 ESR1 ERBB2 EGFR
23 12.03 TP53 MLH1 EGFR CTSD BCL2
24
Show member pathways
11.99 PGR ESR2 ESR1 AR
25 11.88 ESR2 ESR1 AR
26 11.88 TP53 CDK4 BCL2
27
Show member pathways
11.84 ESR1 ERBB2 EGFR
28 11.82 TP53 TOP2A CDK4
29
Show member pathways
11.8 TP53 BRCA2 BRCA1
30 11.79 TP53 MLH1 BRCA2 BRCA1
31 11.76 TP53 KRT5 GATA3
32 11.74 GATA3 ESR1 AR
33 11.73 TP53 ERBB2 EGFR CDK4
34 11.65 ERBB2 BRCA1 BCL2
35 11.64 TP53 ERBB2 BRCA1
36 11.63 KLK3 BRCA1 AR
37 11.6 ESR1 CDK4 BRCA1 BCL2
38 11.53 BRCA1 CTSD ESR1 ESR2 PGR
39 11.51 TOP2A KRT5 BRCA2
40 11.47 BRCA1 CDK4 TP53
41 11.46 TP53 ESR1 EGFR CYP19A1 CDK4 BRCA2
42
Show member pathways
11.42 TP53 TOP2A MLH1
43 11.41 TP53 ERBB2 EGFR CDK4
44 11.38 TP53 ESR1 CTSD
45 11.36 BRCA2 CDK4 ESR1
46 11.36 TP53 CDK4 BRCA1 BCL2
47 11.33 KLK3 ESR1 BRCA1 AR
48 11.3 TP53 CDK4 BRCA1
49 11.28 TP53 TOP2A EGFR
50 11.21 ESR2 ESR1 BCL2

GO Terms for Female Breast Cancer

Cellular components related to Female Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.6 TP53 TOP2A KLK3 ESR1 EGFR CDK4
2 nuclear ubiquitin ligase complex GO:0000152 9.46 BRCA2 BRCA1
3 condensed chromosome GO:0000793 9.26 TOP2A MLH1 BRCA1

Biological processes related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-templated transcription GO:0045893 10.31 TP53 GATA3 ESR2 ESR1 EGFR BRCA2
2 cellular response to DNA damage stimulus GO:0006974 10.21 TP53 TOP2A MLH1 BRCA2 BRCA1 BCL2
3 negative regulation of cell growth GO:0030308 10.17 TP53 ESR2 BRCA1 BCL2
4 positive regulation of gene expression GO:0010628 10.15 AR BRCA1 ERBB2 GATA3 PGR PIP
5 male gonad development GO:0008584 10.13 GATA3 ESR1 BCL2 AR
6 cellular response to estradiol stimulus GO:0071392 10.08 ESR2 ESR1 EGFR
7 cellular response to ionizing radiation GO:0071479 10.03 BRCA1 BRCA2 TP53
8 T cell differentiation in thymus GO:0033077 10 TP53 GATA3 BCL2
9 cell population proliferation GO:0008283 9.95 BCL2 BRCA2 EGFR GATA3 TP53
10 negative regulation of reactive oxygen species metabolic process GO:2000378 9.93 TP53 BRCA1 BCL2
11 intracellular estrogen receptor signaling pathway GO:0030520 9.91 ESR2 ESR1 AR
12 B cell lineage commitment GO:0002326 9.89 BCL2 TP53
13 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.88 ESR1 TP53
14 morphogenesis of an epithelial fold GO:0060571 9.85 EGFR AR
15 negative regulation of mammary gland epithelial cell proliferation GO:0033600 9.84 GATA3 BRCA2
16 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.8 PGR AR
17 uterus development GO:0060065 9.8 GATA3 ESR1 CYP19A1
18 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.8 MLH1 BRCA2 BRCA1 BCL2
19 chordate embryonic development GO:0043009 9.79 BRCA2 BRCA1
20 T cell lineage commitment GO:0002360 9.79 TP53 BCL2
21 immune system development GO:0002520 9.76 BCL2 GATA3
22 positive regulation of miRNA transcription GO:1902895 9.63 AR EGFR GATA3 TP53
23 positive regulation of miRNA maturation GO:1903800 9.62 TP53 EGFR
24 response to gamma radiation GO:0010332 9.56 TP53 GATA3 BRCA2 BCL2
25 intracellular steroid hormone receptor signaling pathway GO:0030518 9.23 PGR ESR2 ESR1 AR

Molecular functions related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.49 BCL2 BRCA1 BRCA2 EGFR ERBB2 ESR1
2 chromatin binding GO:0003682 10.29 TP53 TOP2A MLH1 ESR1 EGFR AR
3 sequence-specific DNA binding GO:0043565 9.98 PGR GATA3 ESR2 ESR1 BCL2 AR
4 ATPase binding GO:0051117 9.97 AR EGFR ESR1 PGR
5 protein phosphatase binding GO:0019903 9.95 TP53 ERBB2 EGFR BCL2
6 nuclear receptor activity GO:0004879 9.86 PGR ESR2 ESR1 AR
7 estrogen response element binding GO:0034056 9.78 ESR2 ESR1
8 nuclear estrogen receptor activity GO:0030284 9.76 ESR2 ESR1
9 transcription coactivator binding GO:0001223 9.76 PGR GATA3 ESR1 AR
10 nuclear steroid receptor activity GO:0003707 9.72 PGR ESR2 ESR1
11 enzyme binding GO:0019899 9.58 TP53 TOP2A PGR MLH1 ESR2 ESR1
12 steroid binding GO:0005496 9.56 AR ESR1 ESR2 PGR

Sources for Female Breast Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....